07:00 , Jun 17, 2013 |  BioCentury  |  Strategy

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
07:00 , May 13, 2013 |  BC Week In Review  |  Company News

Drais, Tacurion, Astellas deal

Astellas and Drais partnered to form virtual company Tacurion to develop and commercialize Astellas' ASP7035 for nocturia. Tacurion will own all rights and assets related to the vasopressin 2 (V2) receptor agonist, which...
00:19 , May 8, 2013 |  BC Extra  |  Company News

Astellas, Drais form newco to develop Astellas nocturia compound

Astellas Pharma Inc. (Tokyo:4503) and Drais Pharmaceuticals Inc. (Bridgewater, N.J.) partnered to form a virtual company -- Tacurion Pharma Inc. -- to develop and commercialize Astellas' ASP7035 for nocturia. Tacurion will own all rights and...